Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.

Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.
复制标题

用于治疗细胞内感染的药物输送方法的荟萃分析。

DOI:
10.1007/s11095-022-03188-z
复制
发表时间:
2022-06
影响因子:
3.7
通讯作者:
Yeo Y
Yeo Y
中科院分区:
医学3区
文献类型:
--
作者:
Shin S;Kwon S;Yeo Y

文献摘要

参考文献

相似文献

本荟萃分析旨在评价抗菌药物细胞内递送研究的趋势、方法学质量和完整性。检索PubMed, Embase和相关综述的参考文献列表,以确定评估载体介导的细胞内递送和抗菌药物在体外和/或体内对细胞内病原体的药效学(PD)的原始文章。共有99项研究被纳入分析。最常见的细胞内病原体是细菌(62.6%),其次是病毒(16.2%)和寄生虫(15.2%)。99项研究中有21项(21.2%)既没有进行显微镜成像,也没有进行流式细胞术分析,以证实感染细胞中存在载体颗粒。只有31.3%的研究提供了与游离药物对照的比较抑制浓度。大约8%的研究,尽管声称抗菌药物在细胞内传递,但没有提供任何实验数据,如显微镜成像、流式细胞术和体外PD。未来对抗菌药物细胞内递送的研究需要提高方法学质量和支持数据的完整性,以促进抗菌药物细胞内递送平台的临床转化。在线版本包含补充材料,可在10.1007/s11095-022-03188-z获得。
This meta-analysis aims to evaluate the trend, methodological quality and completeness of studies on intracellular delivery of antimicrobial agents. PubMed, Embase, and reference lists of related reviews were searched to identify original articles that evaluated carrier-mediated intracellular delivery and pharmacodynamics (PD) of antimicrobial therapeutics against intracellular pathogens in vitro and/or in vivo. A total of 99 studies were included in the analysis. The most commonly targeted intracellular pathogens were bacteria (62.6%), followed by viruses (16.2%) and parasites (15.2%). Twenty-one out of 99 (21.2%) studies performed neither microscopic imaging nor flow cytometric analysis to verify that the carrier particles are present in the infected cells. Only 31.3% of studies provided comparative inhibitory concentrations against a free drug control. Approximately 8% of studies, albeit claimed for intracellular delivery of antimicrobial therapeutics, did not provide any experimental data such as microscopic imaging, flow cytometry, and in vitro PD. Future research on intracellular delivery of antimicrobial agents needs to improve the methodological quality and completeness of supporting data in order to facilitate clinical translation of intracellular delivery platforms for antimicrobial therapeutics. The online version contains supplementary material available at 10.1007/s11095-022-03188-z.
DOI: 10.1371/journal.pone.0184793
发表时间: 2017
期刊: PloS one
影响因子: 3.7
作者:
Brockman SM;Bodas M;Silverberg D;Sharma A;Vij N
通讯作者: Vij N
DOI: 10.3390/nano11051086
发表时间: 2021-04-22
期刊: Nanomaterials (Basel, Switzerland)
影响因子: --
作者:
Arshad R;Tabish TA;Kiani MH;Ibrahim IM;Shahnaz G;Rahdar A;Kang M;Pandey S
通讯作者: Pandey S
DOI: 10.1016/j.intimp.2021.107457
发表时间: 2021-03-20
影响因子: 5.6
作者:
Diez-Orejas, R.;Casarrubios, L.;Portoles, M. T.
通讯作者: Portoles, M. T.
DOI: 10.1007/s11095-011-0622-3
发表时间: 2012-06-01
影响因子: 3.7
作者:
das Neves, Jose;Michiels, Johan;Sarmento, Bruno
通讯作者: Sarmento, Bruno
DOI: 10.2323/jgam.53.333
发表时间: 2007-12-01
影响因子: 1.2
作者:
Chaturvedi, Vinita;Dwivedi, Namrata;Sinha, Sudhir
通讯作者: Sinha, Sudhir